Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > Let’s make some noise!

<< Previous

Bullboard Posts

Next >>

Post by Moonshiner592on Feb 22, 2021 10:05pm

243 Views

Post# 32633716

Let’s make some noise!

Guys - The length of this halt is absolutely ridiculous!

We need to move forward with business!

Care to send your thoughts directly to the TSE?

!! Just Do it !!

Janice Harrington

Team Manager, Listings

TSX Venture Exchange

T604-647-7038

ejanice.harrington@tmx.com

Joanne Butz, CPA, CMA, CFE

Team Manager, Compliance & Disclosure, TSX Venture Exchange

TSX Venture Exchange Inc.

Phone: +1 403-218-2820 ; Cell: +1-403-560-1290

Email: joanne.butz@tmx.com

<< Previous

Bullboard Posts